DOCSLIB.ORG

Toxicological Profile for Lead/Metals Division

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxicological Profile for Lead/Metals Division LEAD 415 9. REFERENCES Abadin HG, Hibbs BF, Pohl HR. 1997b. Breast-feeding exposure of infants to cadmium, lead, and mercury: A public health viewpoint. Toxicol Ind Health 15(4):1-24. Abadin HG, Wheeler JS, Jones DE, et al. 1997a. A framework to guide public health assessment decisions at lead sites. J Clean Technol Environ Toxicol Occup Med 6:225-237. Abbate C, Buceti R, Munao F, et al. 1995. Neurotoxicity induced by lead levels: An electrophysiological study. Int Arch Occup Environ Health 66:389-392. ACGIH. 1986. Documentation of the threshold limit values and biological exposure indices. 5th ed. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, BEI-19 to BEI-23. ACGIH. 1998. 1998 TLVs and BEIs. Threshold limit values for chemical substances and physical agents. Biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienist. ACGIH. 2004. Lead. Threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. Adebonojo FO. 1974. Hematologic status of urban black children in Philadelphia: Emphasis on the frequency of anemia and elevated blood lead levels. Clin Pediatr 13:874-888. Adhikari N, Sinha N, Narayan R, et al. 2001. Lead-induced cell death in testes of young rats. J Appl Toxicol 21:275-277. Adinolfi M. 1985. The development of the human blood-CSF-brain barrier. Dev Med Child Neurol 27:532-537. Agency for Toxic Substances and Disease Registry. 1989. Decision guide for identifying substance- specific data needs related to toxicological profiles; notice. Fed Regist 54(174):37618-37634. Agency for Toxic Substances and Disease Registry. 1995. Multisite lead and cadmium exposure study with biological markers incorporated. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. Agency for Toxic Substances and Disease Registry. 1997. Public health statement for lead. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. Agency for Toxic Substances and Disease Registry. 2004a. Interaction profile for arsenic, cadmium, chromium, and lead. Atlanta, GA: Agency for Toxic Substances and Disease Registry. http://www.atsdr.cdc.gov/interactionprofiles/ip04.html. July 22, 2005. Agency for Toxic Substances and Disease Registry. 2004b. Interaction profile for lead, manganese, zinc, and copper. Atlanta, GA: Agency for Toxic Substances and Disease Registry. http://www.atsdr.cdc.gov/interactionprofiles/ip06.html. July 22, 2005. _______________________ *Not cited in text LEAD 416 9. REFERENCES Agency for Toxic Substances and Disease Registry. 2006. Interaction profile for chlorpyrifos, lead, mercury, and methylmercury. Atlanta, GA: Agency for Toxic Substances and Disease Registry. http://www.atsdr.cdc.gov/interactionprofiles/IP-11/ip11.pdf. June 14, 2007. Aguilera de Benzo Z, Fraile R, Carrion N, et al. 1989. Determination of lead in whole blood by electrothermal atomization atomic absorption spectrometry using tube and platform atomizers and dilution with Triton X-100. J Anal Atom Spectrom 4:397-400. Ahamed M, Verma S, Kumar A, et al. 2005. Environmental exposure to lead and its correlation with biochemical indices in children. Sci Total Environ 346(1-3):48-55. Ahlgren L, Liden S, Mattson, et al. 1976. X-ray fluorescence analysis of lead in human skeleton in vivo. Scand J Work Environ Health 2:82-86. *Ahmed NS, El-Gendy KS, El-Refaie AK et al. 1987. Assessment of lead toxicity in traffic controllers of Alexandria, Egypt, road intersections. Arch Environ Health 42:92-95. Aiba Y, Ohshiba S, Horiguchi S, et al. 1999. Peripheral hemodynamics evaluated by acceleration plethysmography in workers exposed to lead. Ind Health 37:3-8. Åkesson A, Stal P, Vahter M. 2000. Phlebotomy increases cadmium uptake in hemochromatosis. Environ Health Perspect 108:289-291. Al-Hakkak ZSH, Hamamy HA, Murad AMB, et al. 1986. Chromosome aberrations in workers at a storage battery plant in Iraq. Mutat Res 171:53-60. Al Khayat A, Habibullah J, Koutouby A, et al. 1997b. Correlation between maternal and cord blood lead levels. Int J Environ Health Res 7(4):323-328. Al Khayat A, Menon NS, Alidina MR. 1997a. Acute lead encephalopathy in early infancy-clinical presentation and outcome. Ann Trop Paediatr 17(1):39-44. Al-Modhefer AJA, Bradbury MWB, Simmons TJB. 1991. Observations on the chemical nature of lead in human blood serum. Clin Sci 81:823-829. Al-Neamy FR, Almehdi AM, Alwash R, et al. 2001. Occupational lead exposure and amino acid profiles and liver function tests in industrial workers. Int J Environ Health Res 11(2):181-188. Al-Rashdan A, Heitkemper D, Caruso JA. 1991. Lead speciation by HPLC-ICP-AES and HPLC-ICP­ MS. J Chromatogr Sci 29(3):98-102. Al-Saleh I, Nester M, DeVol E, et al. 2001. Relationship between blood lead concentrations, intelligence, and academic achievement of Saudi Arabian schoolgirls. Int J Hyg Environ Health 204:165­ 174. Al-Saleh I, Shinwari N, Mashour A, et al. 2005. Is lead considered as a risk factor for high blood pressure during menopause period among Saudi women? Int J Hyg Environ Health 208(5):341-356. Alessio L. 1988. Relationships between “chelatable lead” and the indicators of exposure and effect in current and past occupational life. Sci Total Environ 71:293-299. LEAD 417 9. REFERENCES Alessio L, Bertazzi PA, Monelli O, et al. 1976. Free erythrocyte protoporphyrin as an indicator of the biological effect of lead in adult males: II. Comparison between free erythrocyte protoporphyrin and other indicators of effect. Int Arch Occup Environ Health 37:89-105. Alexander FW, Delves HT. 1981. Blood lead levels during pregnancy. Int Arch Occup Environ Health 48:35-39. Alexander BH, Checkoway H, Costa-Mallen P, et al. 1998b. Interaction of blood lead and δ­ aminolevulinic acid dehydratase genotype on markers of heme synthesis and sperm production in lead smelter workers. Environ Health Perspect 106:213-216. Alexander BH, Checkoway H, Faustman EM, et al. 1998a. Contrasting associations of blood and semen lead concentrations with semen quality among lead smelter workers. Am J Ind Med 34:464-469. Alexander BH, Checkoway H, van Netten C, et al. 1996. Semen quality of men employed at a lead smelter. Occup Environ Med 53:411-416. Alexander FW, Clayton BE, Delves HT. 1974. Mineral and trace-metal balances in children receiving normal and synthetic diets. QJ Med 43:89-111. Allen LB, Siitonen PH, Thompson HC. 1998. Determination of copper, lead, and nickel in edible oils by plasma and furnace atomic spectroscopies. J Am Oil Chem Soc 75(4):477-481. Allen-Gil SM, Gubala CP, Landers DH, et al. 1997. Heavy metal accumulation in sediment and freshwater fish in U.S. arctic lakes. Environ Toxicol Chem 16(4):733-741. Alomran AH, Shleamoon MN. 1988. The influence of chronic lead exposure on lymphocyte proliferative response and immunoglobulin levels in storage battery workers. J Biol Sci Res 19:575-585. Altman PL, Dittmer DS. 1974. Biological handbooks: Biology data book. Vol. III. 2nd ed. Bethesda, MD: Federation of American Societies for Experimental Biology, 1987-2008, 2041. Altmann L, Sveinsson K, Kraemer U, et al. 1998. Visual functions in 6-year-old children in relation to lead and mercury levels. Neurotoxicol Teratol 20(1):9-17. Alvares AP, Kapelner S, Sassa S, et al. 1975. Drug metabolism in normal children, lead-poisoned children, and normal adults. Clin Pharmacol Ther 17:179-183. American Academy of Pediatrics. 1998. Screening for elevated blood lead levels. Policy statement. Committee on environmental health. Pediatrics 101(6):1072-1078. Amitai Y, Graef JW, Brown MJ, et al. 1987. Hazards of deleading homes of children with lead poisoning. Am J Dis Child 141:758-760. Anders E, Bagnell CR, Krigman M, et al. 1982. Influence of dietary protein composition on lead absorption in rats. Bull Environ Contam Toxicol 28:61-67. Andersen ME, Krishnan K. 1994. Relating in vitro to in vivo exposures with physiologically based tissue dosimetry and tissue response models. In: Salem H, ed. Animal test alternatives: Refinement, reduction, replacement. New York: Marcel Dekker, Inc., 9-25. LEAD 418 9. REFERENCES Andersen ME, Clewell HJ III, Gargas ML, et al. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205. Anderson RJ. 1987. Peripheral nerve conduction velocities and excitability. In: Lowndes HE, ed. Electrophysiology in neurotoxicology, Vol. 11. Piscataway, NJ: Department of Pharmacology and Toxicology, 51-69. Angle CR, Kuntzelman DR. 1989. Increased erythrocyte protoporphyrins and blood lead--a pilot study of childhood growth patterns. J Toxicol Environ Health 26:149-156. Angle CR, McIntire MS. 1978. Low level lead and inhibition of erythrocyte pyrimidine nucleotidase. Environ Res 17:296-302. Angle CR, Manton WI, Stanek KL. 1995. Stable isotope identification of lead sources in preschool children: The Omaha study. Clin Toxicol 33(6):657-662. Angle CR, Marcus A, Cheng I-H, et al. 1984. Omaha childhood blood lead and environmental lead: A linear total exposure model. Environ Res 35:160-170. Angle CR, McIntire MS, Swanson MS, et al. 1982. Erythrocyte nucleotides in children--increased blood lead and cytidine triphosphate. Pediatr Res 16:331-334. Annesi-Maesano I, Pollitt R, King G, et al. 2003. In utero exposure to lead and cord blood total IgE. Is there a connection? Allergy 58:589-594. Anttila A, Heikkila P, Nykyri E, et al. 1996. Risk of nervous system cancer among workers exposed to lead. J Occup Environ Med 38(2):131-136. Anttila A, Heikkila P, Pukkala E, et al. 1995. Excess lung cancer among workers exposed to lead. Scand J Work Environ Health 21:460-469. APHA. 1998. Method 3111.
Load more

Recommended publications
  • FDA Guidance on Establishing Pregnancy Exposure Registries
    Guidance for Industry Establishing Pregnancy Exposure Registries U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical Guidance for Industry Establishing Pregnancy Exposure Registries Additional copies are available from: Office of Training and Communications Division of Communications Management Drug Information Branch, HFD-210 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm or Office of Communication, Training, and Manufacturers Assistance (HFM-40) Center for Biologics Evaluation and Research (CBER) 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/cber/guidelines.htm (Fax) 888-CBERFAX or 301-827-3844 (Voice Information) 800-835-4709 or 301-827-1800 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical TABLE OF CONTENTS I. INTRODUCTION................................................................................................................. 1 II. BACKGROUND ...................................................................................................................1 III. WHAT IS A PREGNANCY EXPOSURE REGISTRY? .................................................. 2 IV. WHAT MEDICAL PRODUCTS MAKE GOOD REGISTRY CANDIDATES?........... 3 V. WHEN SHOULD SUCH A REGISTRY BE ESTABLISHED?......................................
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Conventional Gasoline
    Conventional Gasoline M a t e r i a l S a f e t y D a t a S h e e t 1. PRODUCT AND COMPANY IDENTIFICATION Product Name: Conventional Gasoline MSDS Code: 251720 Synonyms: Gasoline, Unleaded, Conventional (All Grades); Gasoline, Low Sulfur Unleaded (All Grades) Intended Use: Fuel Responsible Party: ConocoPhillips 600 N. Dairy Ashford Houston, Texas 77079-1175 Customer Service: 800-640-1956 Technical Information: 800-255-9556 MSDS Information: Phone: 800-762-0942 Email: [email protected] Internet: http://w3.conocophillips.com/NetMSDS/ Emergency Telephone Numbers: Chemtrec: 800-424-9300 (24 Hours) California Poison Control System: 800-356-3219 2. HAZARDS IDENTIFICATION Emergency Overview NFPA DANGER! Extremely Flammable Liquid and Vapor Skin Irritant Aspiration Hazard Appearance: Clear to amber Physical Form: Liquid Odor: Gasoline Potential Health Effects Eye: Contact may cause mild eye irritation including stinging, watering, and redness. Skin: Skin irritant. Contact may cause redness, itching, a burning sensation, and skin damage. Prolonged or repeated contact can defat the skin, causing drying and cracking of the skin, and possibly dermatitis (inflammation). Not acutely toxic by skin absorption, but prolonged or repeated skin contact may be harmful (see Section 11). Inhalation (Breathing): Low to moderate degree of toxicity by inhalation. Ingestion (Swallowing): Low degree of toxicity by ingestion. ASPIRATION HAZARD - This material can enter lungs during swallowing or vomiting and cause lung inflammation and damage. Signs and Symptoms: Effects of overexposure may include nausea, vomiting, flushing, blurred vision, tremors, respiratory failure, signs of nervous system depression (e.g., headache, drowsiness, dizziness, loss of coordination, disorientation and fatigue), unconsciousness, convulsions, death.
    [Show full text]
  • Committee for Risk Assessment RAC Opinion Proposing Harmonised
    Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of 2-Ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex EC Number: - CAS Number: - CLH-O-0000006817-63-01/F Adopted 11 June 2020 P.O. Box 400, FI-00121 Helsinki, Finland | Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu [04.01-ML-014.03] 11 June 2020 CLH-O-0000006817-63-01/F OPINION OF THE COMMITTEE FOR RISK ASSESSMENT ON A DOSSIER PROPOSING HARMONISED CLASSIFICATION AND LABELLING AT EU LEVEL In accordance with Article 37 (4) of Regulation (EC) No 1272/2008, the Classification, Labelling and Packaging (CLP) Regulation, the Committee for Risk Assessment (RAC) has adopted an opinion on the proposal for harmonised classification and labelling (CLH) of: Chemical name: 2-Ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex EC Number: - CAS Number: - The proposal was submitted by Spain and received by RAC on 16 April 2019. In this opinion, all classification and labelling elements are given in accordance with the CLP Regulation. PROCESS FOR ADOPTION OF THE OPINION Spain has submitted a CLH dossier containing a proposal together with the justification and background information documented in a CLH report. The CLH report was made publicly available in accordance with the requirements of the CLP Regulation at http://echa.europa.eu/harmonised-classification-and-labelling-consultation/ on 27 May 2019. Concerned parties and Member State Competent Authorities (MSCA) were invited to submit comments and contributions by 26 July 2019.
    [Show full text]
  • Investigating the Role of Heme Oxygenase and Oxidative Stress in Oesophagogastric Cancer
    Investigating the Role of Heme Oxygenase and Oxidative Stress in Oesophagogastric Cancer Oliver Hartwell Priest Department of Surgery and Cancer Imperial College London St Mary’s Campus London, UK A thesis submitted to Imperial College London for the degree of Doctorate of Philosophy Supervisors Professor George Hanna Department of Surgery and Cancer, Imperial College London St Mary’s Campus, London, UK Dr Nandor Marczin Department of Anaesthetics, Pain Medicine and Intensive Care Imperial College London, Chelsea and Westminster Campus, London, UK 2 ABSTRACT Background: Molecular mechanisms underlying gastric and oesophageal cancer include alterations in growth factors, cytokines and cell adhesion molecules. Heme oxygenase (HO) enzyme catalyses the degradation of heme and generates bilirubin and carbon monoxide that have antioxidant, anti-inflammatory and anti-apoptotic activities. HO enzyme is implicated in the biology of cancer by its effects on cell growth and resistance to apoptosis. The roles of HO-1 and HO-2 enzymes in cancer cell growth are poorly understood, with reports suggesting both anti-inflammatory, anti-tumour effects and tumour-protective mechanisms mediated by HO activity. The role of HO-2 in inflammation and cancer is largely unexplored. Further understanding the influence of the HO enzyme system may provide improved novel targets for oesophagogastric cancer therapy. Materials and Methods: The primary objective of the thesis was to characterise the role of the heme oxygenase pathway and modulation of HO activity in upper gastrointestinal cancer cell growth in vitro. Cell culture techniques included MTT growth assay, Western blotting protein analysis, pharmacological modulation of HO activity and targeted knockdown of HO mRNA.
    [Show full text]
  • Guidelines for Developmental Toxicity Risk Assessment
    EPA/600/FR-91/001 December 1991 Guidelines for Developmental Toxicity Risk Assessment Published on December 5, 1991, Federal Register 56(234):63798-63826 Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document represents the final guidelines. A number of editorial corrections have been made during conversion and subsequent proofreading to ensure the accuracy of this publication. ii CONTENTS Lists of Tables and Figures ........................................................v Federal Register Preamble ....................................................... vi Part A: Guidelines for Developmental Toxicity Risk Assessment 1. Introduction ................................................................1 2. Definitions and Terminology ....................................................3 3. Hazard Identification/Dose-Response Evaluation of Agents That Cause Developmental Toxicit y 4 3.1. Developmental Toxicity Studies: Endpoints and Their Interpretation ..................5 3.1.1. Laboratory Animal Studies ..........................................5 3.1.1.1 Endpoints of Maternal Toxicity . 7 3.1.1.2. Endpoints of Developmental Toxicity: Altered Survival, Growth, and Morphological Development ........................9 3.1.1.3. Endpoints of Developmental Toxicity: Functional
    [Show full text]
  • Formation of Zinc Protoporphyrin Ix During the Production Process of Dry Fermented Sausages
    FORMATION OF ZINC PROTOPORPHYRIN IX DURING THE PRODUCTION PROCESS OF DRY FERMENTED SAUSAGES H. De Maere1,2*, E. De Mey2, L. Dewulf², H. Paelinck², S. Chollet1 and I. Fraeye² 1 Food Quality Laboratory, Groupe ISA, Lille Cedex, France 2 Research Group for Technology and Quality of Animal Products, KAHO, Ghent, Belgium, member of Leuven Food Science and Nutrition Research Centre (LFoRCe), KULeuven, Leuven, Belgium Abstract – The aim of this study was to follow the stable red colour without any addition of nitrite or formation of zinc protoporphyrin IX (ZPP) during nitrate. Wakamatsu et al. [6] [7] assigned the the production process of dry fermented sausages. bright red colour of Parma ham to the presence of Three batches were made, with the addition of zinc protoporphyrin IX (ZPP), wherein the ferrous nitrite salt, sodium chloride or sea salt, respectively. ion in the heme molecule is replaced by zinc. The formation of ZPP was largely inhibited by nitrite during production of dry fermented sausages. Three possible formation pathways have been In nitrite-free dry fermented sausages ZPP was suggested, (i) a slow non-enzymatic reaction; (ii) a formed during production. In this study, the use of bacterial enzymatic reaction, and (iii) an sea salt had a positive effect on the formation of ZPP, enzymatic reaction where an endogenous especially during the fermentation period. ferrochelatase interchanges the two metals Fe(II) and Zn(II) [8] [9]. Key Words – ZPP, Colour, Sodium nitrite, Sea salt ZPP is also present in other meat products such as the Spanish Iberian ham, lacking nitrite or nitrate I.
    [Show full text]
  • Quo Vadis Porphyrin Chemistry?
    Physiol. Res. 55 (Suppl. 2): S3-S26, 2006 Quo vadis porphyrin chemistry? V. KRÁL1,2* J. KRÁLOVÁ3, R. KAPLÁNEK1,4, T. BŘÍZA1,4, P. MARTÁSEK4* 1Department of Analytical Chemistry, Institute of Chemical Technology, 2Zentiva R & D, 3Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 4First Medical Faculty, Charles University, Prague, Czech Republic Received March 22, 2006 Accepted June 23, 2006 Summary This review summarizes recent developments in the area of porphyrin chemistry in the direction of biological applications. Novel synthetic methodologies are reviewed for porphyrin synthesis, porphyrin analog synthesis, stable porphyrinogens - calixpyrroles, expanded porphyrins. Unique biological properties of those compounds are desribed with focus on photodynamic therapy (PDT) and molecular recognition properties. Special attentions given to metalloporphyrins with potential to affect heme degradation and CO formation. Key words Porphyrins • Synthesis • Expanded porphyrins • Photosenzitizers • Molecular recognition • Metalloporphyrins 1. Porphyrin skelet in nature enzymes that are evolutionarily conserved from bacteria to humans. Naturally occuring porphyrins are synthesized Hem is ferroprotoporphyrin complex. The basis by living matter. Among the best known natural of the structure is the porphyrin skelet, which is formed structures utilizing porphyrin skelet are vitamin B12 by four pyrroles linked with four methine bridges. The (Fig. 1), chlorophyll (Fig. 3), uroporphyrins, substituents, four methyls, two vinyls and two propionic coproporphyrins and heme (Fig. 2). side chains, in beta positions of pyrroles, can be arranged In the natural system, vitamin B12 is known to by fifteenth modality, but only one of these isomers, have a contracted porphyrin framework which is known called Protoporphyrin IX, is present in living systems.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof The requirement for cobalt in vitamin B12: A paradigm for protein metalation Deenah Osman, Anastasia Cooke, Tessa R. Young, Evelyne Deery, Nigel J. Robinson, Martin J. Warren PII: S0167-4889(20)30254-8 DOI: https://doi.org/10.1016/j.bbamcr.2020.118896 Reference: BBAMCR 118896 To appear in: BBA - Molecular Cell Research Received date: 8 July 2020 Revised date: 13 October 2020 Accepted date: 14 October 2020 Please cite this article as: D. Osman, A. Cooke, T.R. Young, et al., The requirement for cobalt in vitamin B12: A paradigm for protein metalation, BBA - Molecular Cell Research (2020), https://doi.org/10.1016/j.bbamcr.2020.118896 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Journal Pre-proof The requirement for cobalt in vitamin B12: A paradigm for protein metalation Deenah Osmana, b, Anastasia Cookec, Tessa R. Younga, b, Evelyne Deeryc, Nigel J. Robinsona,b, Martin J. Warrenc, d, e, aDepartment of Biosciences, Durham University, Durham, DH1 3LE, UK. bDepartment of Chemistry, Durham University, Durham, DH1 3LE, UK.
    [Show full text]
  • Data Sheet Template
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME DBL™ Aciclovir Intravenous Infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DBL™ Aciclovir Intravenous Infusion contains the equivalent of 25 mg/mL of aciclovir; the aciclovir is present as aciclovir sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for Infusion DBL™ Aciclovir Intravenous Infusion is a clear colourless or almost colourless sterile solution. DBL™ Aciclovir Intravenous Infusion has a pH of approximately 11. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications DBL™ Aciclovir Intravenous Infusion is indicated for the treatment of Herpes simplex infections. DBL™ Aciclovir Intravenous Infusion is indicated for the prophylaxis of Herpes simplex infections in immune-compromised patients. DBL™ Aciclovir Intravenous Infusion is indicated in the treatment of Varicella zoster infections. DBL™ Aciclovir Intravenous Infusion is indicated for the treatment of Herpes simplex infections in the neonate. DBL™ Aciclovir Intravenous Infusion formulations are indicated for prophylaxis of CMV infection in bone marrow transplant recipients. It has been shown that high dose intravenous aciclovir reduces the incidence and delays the onset of CMV infection. When high dose intravenous aciclovir is followed by 6 months treatment with high dose oral aciclovir (see prescribing information for oral aciclovir) mortality and the incidence of viraemia are also reduced. Version 6.0 Page 1 of 10 4.2 Dose and method of administration Dosage in adults Patients with Herpes simplex (except herpes encephalitis) or Varicella zoster infections should be given DBL™ Aciclovir Intravenous Infusion in doses of 5 mg/kg bodyweight every 8 hours. Immune-compromised patients with Varicella zoster infections or patients with herpes encephalitis should be given DBL™ Aciclovir Intravenous Infusion in doses of 10 mg/kg bodyweight every 8 hours provided renal function is not impaired.
    [Show full text]
  • Report on the Deliberation Results March 8, 2018 Pharmaceutical
    Report on the Deliberation Results March 8, 2018 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Shingrix for Intramuscular Injection Non-proprietary Name Dried Recombinant Herpes Zoster Vaccine (Derived from Chinese Hamster Ovary Cells) Applicant Japan Vaccine Co., Ltd. Date of Application April 18, 2017 Results of Deliberation In its meeting held on March 2, 2018, the Second Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is classified as a biological product, and the re-examination period is 8 years. The drug product and its drug substance are both classified as powerful drugs. Conditions of Approval The applicant is required to develop and appropriately implement a risk management plan. This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report February 13, 2018 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Shingrix for Intramuscular Injection Non-proprietary Name Dried Recombinant Herpes Zoster Vaccine (Derived from Chinese Hamster Ovary Cells) Applicant Japan Vaccine Co., Ltd.
    [Show full text]
  • Developmental Toxicology Drugs, and Fetal Teratogenesis
    Brent, RL and Fawcett, LB: Developmental toxicology, drugs, and fetal teratogenesis. In Reece EA, Hobbins JC (eds.) Clinical Obstetrics: The Fetus and Mother, 3rd edition, Blackwell Publishing Inc., Malden, MA, Chapter 15, pp. 217-235, 2007. Developmental toxicology, drugs, and fetal teratogenesis Robert L. Brent and Lynda B. Fawcett Reproductive problems encompass a multiplicity of diseases example, environmental agents dispensed by healthcare including sterility, infertility, abortion (miscarriage), stillbirth, providers or utilized by emp10yers.l.~ congenital malformations (resulting from environmental or Reproductive problems alarm the public, the press, and sci- hereditary etiologies), fetal growth retardation, and prematu- entists to a greater degree than many other diseases. Severely rity. These clinical problems occur commonly in the general malformed children are disquieting to healthcare providers, population and, therefore, environmental causes are not especially if they are not experienced in dealing with such always easy to corroborate (Table 15.1). Severe congenital problems; no physician will be comfortable informing a family malformations occur in 3% of births; according to the Center that their child was born without arms and legs. The objec- for Disease Control, they include those birth defects that cause tive evaluation of the environmental causes of reproductive death, hospitalization, and mental retardation, and those that diseases is clouded by the emotional climate that surrounds necessitate significant or repeated surgical procedures, are dis- these diseases, resulting in the expression of partisan positions figuring, or interfere with physical performance. This means that either diminish or magnify the environmental risks. These that each year in the USA, 120000 babies are born with severe nonobjective opinions can be expressed by scientists, the laity, birth defects.
    [Show full text]